Immuron Ltd — Regulatory Filings 2007

Feb 15, 2007

February 16th, 2007

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Please find herewith a company announcement "Company Portfolio Presentation" for release and distribution to the market immediately.

Yours sincerely

CONOR GRAHAM Managing Director & CEO

Company Portfolio Presentation

February 2007

• Australian Biotechnology company $\bullet$
• Research and products; $\bullet$
• * providing "passive immunity" and treatment to a range of important infectious and immune depleting diseases and,
• ❖ developing novel ingredients to improve the functionality of foods
• Functional / Health food contract manufacturing facility $\bullet$

At market product: Travelar'

Product

Travelan

Helps prevent E.coli caused "Travellers" Diarrhoea

Symptoms include:

• Diarrhoea
• Vomitina
• Nausea
• Bloating and,
• Stomach cramps

No comparable oral product.

Opportunities

Partner with us to market for;

• Travel within Asia.
• Travel between regions. ۰
• Travel to Asia by westerners. ۰
• Travel by Asians to medium high ۰ health risk destinations
• Beijing Olympics. $\bullet$
• IOC has accepted the use of product and Australian sporting team acceptance already in place
• Product launch in Canada & USA in 2007

Market potential for Travelan

Asian market potential exceeds US\$300 million

Assumptions:

• Based on US\$20 retail price per pack $\bullet$
• Conservative estimate of 150 million travellers to, or travel within region, plus travel from region to medium - high risk locations (135 million tourist* arrivals alone to the region)
• 10% customer uptake ۰

* Statistics according the UNWTO (United Nations World Tourism Organisation)

Near term product: $1$ T $6$ O

Product

EVProtec

Neutralising antibodies against Human Enterovirus 71

Disease affects children, predominantly < $6$ years old

Symptoms:

Range from mild fever - death

No comparable oral product

Opportunities

GYPTOLOGI

Karatan Manazarta (Karatan Manazarta )

Partner with us to market in;

• Greater China region ۰
• Malaysia ۰
• Philippines ۰
• Singapore ۰
• South Korea $\bullet$
• Thailand and, ۰
• Vietnam

Market potential for EV-71

Market potential exceeds 1 Billion doses

Albanya (Albanya Albanya) a

Assumptions:

• Conservative estimate of 45 million children $\leq 6$ years old in $\bullet$ countries / territories which could afford product
• 20% customer uptake $\bullet$ (Based on Fear factor / Good parenting - excluding outbreak panic buying)
• Product uptake over 100 days of Summer (high risk season) $\bullet$

Additional markets;

• Older children still at risk (reported deaths up to 16 years old) $\bullet$
• Family & caregivers of at risk group can be carriers, so may $\bullet$ also take product

Mid term product opportunities

Product

Pyloran

H. pylori neutralising antibodies to significantly reduce the infection, and as an adjunct therapy for ulcer treatment.

Small Phase II human clinical trial successfully completed.

Vaccine candidate work proceeding well.

Partner required with the capability to bring product to market. (Potential for "spin off")

Opportunities

1 Gastrointestinal (GI) issue throughout Asia and a problem in the western world

Prevalent in at least 50% of adults, though level of symptoms vary.

gnes
lipies – fizik
lisies 4. ordij 4. vij Korea > 20 milion Jen n Vilmensen US ~ 108 mille UK, France, italy ≈ 70 million

Mid term product opportunities

Product

Opportunities

Travelan IBD

For the treatment and reduction of symptoms associated with Inflammatory Bowel Disease, Crohn's disease and Ulcerative Colitis

Trial in progress, to be completed by September 2007.

No compartive oral product

Market sizes (patients): >70,000 in Australia >1,000,000 in USA $>2,200,000$ throughout EU Emerging issue in Asia, especially India

(NB: Long term patient use)

R&D pipeline

Program

Influenza A Virus:

(epidemic "common" and pandemic "bird flu")

Nosocomial Disease:

Antibiotic resistant, hospital acquired bacterial infections.

Vaccines:

Development & delivery systems

Functional Food additives:

with I.P protection

Opportunities

Inhalable antibodies for the treatment and prevention of flu.

C. Difficile MRSA (Golden Staphylococcus)

Bioshield 10 - oral delivery of vaccines and, H.Pylori vaccine

Delivering specific antibodies and natural anti-oxidants

• Our vision is to utilise our Platform Technologies to make a $\bullet$ positive contribution to human health and well being
• Develop products with a large market potential $\bullet$
• Have unique and proven technology, protected by patents $\bullet$
• Conduct R&D which is cost effective, cutting edge and $\bullet$ flexible
• Actively seek strategic partnership opportunities $\pmb{\circ}$